ArticleDiabetes & metabolism journal2012
Anti-Obesity Drugs: A Review about Their Effects and Safety.
Article in Diabetes & metabolism journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 3 syntheses or guidelines pooled it, 584 citations in OpenAlex.
- The efficacy of topical aminophylline in local fat reduction: A systematic review.Frontiers in endocrinology · 2023Pooled it
- Neural Correlates of Anti-appetite Medications: An fMRI Meta-analysis.Current neuropharmacology · 2021Pooled it
- Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.BMC medicine · 2016Pooled it
- Effect of Amla Extract on Body Mass Index, Waist Circumference, Total Body Fat, Visceral Fat, Skeletal Muscle Mass, Body Age, and Related Parameters: A Randomized, Open-Label Clinical Study in Obese Participants.Complementary medicine research · 2025Trial
- Electro-acupuncture for central obesity: a patient-assessor blinded, randomized sham-controlled clinical trial.BMC complementary medicine and therapies · 2024Trial
- Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial.Scientific reports · 2019Trial
- Beyond weight loss: Integrating GLP-1 RA therapies into psychological and behavioral care for obesity and binge eating disorder.Reviews in endocrine & metabolic disorders · 2026Review
- Ultrasound-assisted extraction of hypolipidemic actives from lotus (Nelumbo nucifera Gaertn.) seedpod: Process optimization, phytochemical characterization, and hypolipidemic activity.Ultrasonics sonochemistry · 2026Article
- Contribution of Phenolic Acid Profiles to the Anti-Adipogenic Activity of DifferentBiomedicines · 2026Article
- Recombinant Macrophage Migration Inhibitory Factor Derived fromInternational journal of molecular sciences · 2026Article
- Evaluation of Functional Properties and the Lipase Inhibitory Activity of Proteins fromRecent advances in food, nutrition & agriculture · 2026Article
- The Effects of Exercise Combined with Pharmacotherapy on Body Composition and Metabolic Parameters in Overweight/Obese Adults: A Meta-Analysis and Network Pharmacology Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Anti-Obesity and Diuretic Effects of Immature Watermelon Rind Extract in HFD-Induced Obese Mice.Nutrients · 2025Article
- Black Cumin Seed (Food science & nutrition · 2025Article
- CRISPR-Cas9 screening reveals microproteins regulating adipocyte proliferation and lipid metabolism.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Regulatory effects of specialized metabolites from Dendrobium albosanguineum on lipid metabolism and adipocyte differentiation.Scientific reports · 2025Article
- The Effects of Wuniuzao Green Tea on Mice With High-Fat Diet-Induced Liver Steatosis.Food science & nutrition · 2025Article
- Combined Potential of Orlistat with Natural Sources and Their Bioactive Compounds Against Obesity: A Review.Molecules (Basel, Switzerland) · 2025Review
- Combining kinetics and in silico approaches to evaluate bromhexine as an anti-pancreatic lipase agent for obesity management.Scientific reports · 2025Article
- Article
158 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current recommendations for the treatment of obese people include increased physical activity and reduced calories intake. When the behavioral approach is not sufficient, a pharmacologic treatment is recommended. In past years, numerous drugs have been approved for the treatment of obesity; however, most of them have been withdrawn from the market because of their adverse effects. In fact, amphetamine, rimonabant and sibutramine licenses have been withdrawn due to an increased risk of psychiatric disorders and non-fatal myocardial infarction or stroke. Even if orlistat is not as effective as other drugs in reducing body weight, orlistat is presently the only available choice for the treatment of obesity because of its safety for cardiovascular events and positive effects on diabetic control. Hopefully, more effective and better tolerated anti-obesity drugs will be developed through an improved understanding of the multiple mechanisms and complex physiological systems targeting appetite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.